Monday, November 05, 2012 11:08:38 PM
Thanks for all that info, I believe we also have trials being run with Perifosine by our partners in specific locations where they've licensed the drug for. While I have no idea what the progress is in these trials, it's possible we could learn something at almost any time. I can't say how significant results could be from any of these trials, but if they're positive they can't hurt.
What I do know is that top notch American Doctor's have relocated to places outside the U.S. where they can get effective drugs that are not yet approved in the U.S., some which might never be. In England there are something like 19 hospitals where patients not in trials can try experimental drugs in protocols which may never have been previously tried, the key is all participating must agree to the protocol. I don't know that news will come out of any such applications, but it's very possible that what's learned in such trials may lead to new FDA approved trials that gain or expand on FDA approvals.
Gary
What I do know is that top notch American Doctor's have relocated to places outside the U.S. where they can get effective drugs that are not yet approved in the U.S., some which might never be. In England there are something like 19 hospitals where patients not in trials can try experimental drugs in protocols which may never have been previously tried, the key is all participating must agree to the protocol. I don't know that news will come out of any such applications, but it's very possible that what's learned in such trials may lead to new FDA approved trials that gain or expand on FDA approvals.
Gary
Recent CSCIF News
- Form SC 13E3/A - Going private transaction by certain issuers: [Amend] • Edgar (US Regulatory) • 05/20/2026 08:46:58 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/20/2026 08:38:12 PM
- Form SC 13E3/A - Going private transaction by certain issuers: [Amend] • Edgar (US Regulatory) • 05/12/2026 09:21:59 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/12/2026 09:07:13 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/12/2026 09:05:51 PM
- COSCIENS Biopharma Inc. Reports Q1 2026 Results • GlobeNewswire Inc. • 05/12/2026 09:05:00 PM
- Form SC 13E3/A - Going private transaction by certain issuers: [Amend] • Edgar (US Regulatory) • 05/08/2026 08:45:33 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2026 08:45:07 PM
- Form SC 13E3 - Going private transaction by certain issuers • Edgar (US Regulatory) • 04/20/2026 12:01:09 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/20/2026 12:00:12 PM
- COSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting Obligations • GlobeNewswire Inc. • 04/20/2026 12:00:00 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 04/17/2026 09:55:15 PM
- COSCIENS Comments on Unusual Market Activity • GlobeNewswire Inc. • 04/07/2026 09:10:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/07/2026 09:07:44 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/25/2026 09:05:27 PM
- COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/25/2026 09:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/19/2026 04:15:19 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 03/13/2026 09:30:57 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 03/13/2026 09:30:39 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 03/13/2026 09:30:14 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/13/2026 09:29:54 PM
